Sparsentan (Filspari) is a new type of oral medication, which was first approved for marketing in the United States in 2023. It is a dual endothelin and angiotensin II receptor antagonist, suitable for specific patients with kidney disease.

What are the Indications of Sparsentan (Filspari)?

Main Indications

Sparsentan (Filspari) is mainly used to slow down the decline of renal function in adult patients with primary immunoglobulin A nephropathy (IgAN), and is suitable for those patients at risk of disease progression.

Primary immunoglobulin A nephropathy is a common chronic glomerular disease, characterized by the deposition of immunoglobulin A in the mesangial area of glomeruli, leading to inflammation and gradual loss of renal function.

By dual antagonism of endothelin A receptor and angiotensin II type 1 receptor, Sparsentan plays a role in reducing proteinuria and protecting renal function.

It should be noted that Sparsentan is not suitable for pediatric patients, and its efficacy has not been established in the minor population.

Specifications and Properties of Sparsentan (Filspari)

Specifications and Dosage Forms

Sparsentan (Filspari) is a film-coated tablet, available in two specifications. It appears as a white to off-white modified oval tablet.

200mg tablet: One side is engraved with the word "105", and the other side is blank.

400mg tablet: One side is engraved with the word "021", and the other side is blank.

Tablets of both specifications are packed in bottles, with 30 tablets per bottle, and are equipped with child-resistant caps.

Ingredient Description

Active ingredient: Sparsentan.

Excipients: Including colloidal silicon dioxide, anhydrous lactose, magnesium stearate, silicified microcrystalline cellulose, sodium carboxymethyl starch, etc.

Film-coating materials: Composed of polyethylene glycol, partially hydrolyzed polyvinyl alcohol, talc powder and titanium dioxide.

Patients should swallow the tablets whole, without chewing or crushing them. The tablets should be taken with water at a fixed time every day (before breakfast or dinner) to maintain stable blood drug concentration.

Storage Method of Sparsentan (Filspari)

Storage Conditions

Sparsentan should be stored in the original packaging bottle to avoid the impact of moisture, light or high temperature.

It is recommended to store it at room temperature between 20°C and 25°C (68°F and 77°F).

Short-term temperature fluctuations between 15°C and 30°C (59°F and 86°F) are allowed.

Moisture and accidental ingestion prevention: The medicine bottle is designed to be difficult for children to open. Please place the medicine out of the reach of children to prevent accidental ingestion.

Prohibition of repackaging: Do not transfer the tablets to other containers, so as to avoid affecting the stability of the medicine or causing confusion.

If patients need to take the medicine for a long time, they should regularly check whether the medicine is within the validity period. Expired or unused medicines should be properly disposed of in accordance with local regulations to avoid environmental pollution or misuse by others.